Material Agreements

Kartoon Studios, Inc. entered into Agreement with Continuation Capital, Inc. valued at $1,143,884 (effective 2026-04-20).

“Kartoon Studios, Inc. (the “Company”) entered into an Agreement (the “Agreement”) with Continuation Capital, Inc. (“CCI”) wherein the Company agreed to issue an aggregate of 2,553,047 shares of its common stock to CCI in exchange for the settlement of certain past due obligations and accounts payable of the Company (the “Subject Debts”) in the aggregate amount of $1,143,884”

Trane Technologies plc terminated 2022 Revolving Credit Agreement with the Borrowers and the Guarantors (effective 2026-04-23).

“The 2026 Revolving Credit Agreement has a term through April 23, 2031 and replaces the $1 billion senior unsecured revolving credit agreement entered into on April 25, 2022, which is expiring April 25, 2027 (the “2022 Revolving Credit Agreement”). The proceeds of the 2026 Revolving Credit Agreement will be used (i) for working capital purposes of TT Parent, any of the Borrowers and their respective subsidiaries, (ii) to support the commercial paper programs of any of the Borrowers and any additional borrowers, (iii) for other general corporate purposes of TT Parent, any of the Borrowers and their respective subsidiaries, and (iv) to repay any amounts outstanding under the 2022 Revolving Credit Agreement.”

Trane Technologies plc entered into 2026 Revolving Credit Agreement with JPMorgan Chase Bank, N.A., as U.S. Administrative Agent and J.P. Morgan SE, as Non-U.S. Administrative Agent; Citibank, N.A., as Syndication Agent; Bank of America, N.A., BNP Paribas Securities Corp., Deutsche Bank Securities Inc., Mizuho Bank, Ltd., U.S. Bank National Association, and Wells Fargo B valued at $1.5 billion (effective 2026-04-23).

“On April 23, 2026, Trane Technologies Holdco Inc. (“TTH”) and Trane Technologies Financing Limited (“TTFL” and, together with TTH, the “Borrowers”), Trane Technologies plc (“TT Parent”), Trane Technologies Lux International Holding Company S.à r.l. (“TT Lux Holding Company”), Trane Technologies Irish Holdings Unlimited Company (“Irish Holdings”), Trane Technologies Americas Holding Corporation (“TTAHC”), Trane Technologies Global Holding II Company Limited (“Trane Global”), and Trane Technologies Company LLC (“TTC” and, together with TT Parent, Irish Holdings TTAHC, Trane Global, and TT Lux Holding Company, the “Guarantors”), JPMorgan Chase Bank, N.A., as U.S. Administrative Agent and J.P. Morgan SE, as Non-U.S. Administrative Agent; Citibank, N.A., as Syndication Agent; Bank of America, N.A., BNP Paribas Securities Corp., Deutsche Bank Securities Inc., Mizuho Bank, Ltd., U.S. Bank National Association, and Wells Fargo Bank, National Association, as Documentation Agents; and JPMorgan C”

Accenture plc terminated Prior $5.5 billion senior unsecured revolving credit facility with various lenders valued at $5.5 billion (effective 2026-04-22).

“The Credit Agreements replace Accenture’s prior $5.5 billion senior unsecured revolving credit facility, which was terminated on April 22, 2026.”

Accenture plc entered into 364-Day Credit Agreement with Bank of America, N.A. (as administrative agent) and the lenders named therein valued at $2.175 billion (effective 2026-04-22).

“On April 22, 2026, Accenture plc (“Accenture”), as guarantor, and certain of Accenture’s subsidiaries, as borrowers (the “Borrowers”), entered into (i) a credit agreement (the “Five-Year Credit Agreement”) with Bank of America, N.A., as administrative agent (the “Agent”), and the lenders named therein (the “Lenders”), which provides for a $5.925 billion senior unsecured revolving credit facility with a term of five years from the date of the Five-Year Credit Agreement and (ii) a 364-day credit agreement (the “364-Day Credit Agreement” and, together with the Five-Year Credit Agreement, the “Credit Agreements”) with the Agent and the Lenders named therein, which provides for a $2.175 billion senior unsecured revolving credit facility with a term of 364-days from the date of the 364-Day Credit Agreement.”

Accenture plc entered into Five-Year Credit Agreement with Bank of America, N.A. (as administrative agent) and the lenders named therein valued at $5.925 billion (effective 2026-04-22).

“On April 22, 2026, Accenture plc (“Accenture”), as guarantor, and certain of Accenture’s subsidiaries, as borrowers (the “Borrowers”), entered into (i) a credit agreement (the “Five-Year Credit Agreement”) with Bank of America, N.A., as administrative agent (the “Agent”), and the lenders named therein (the “Lenders”), which provides for a $5.925 billion senior unsecured revolving credit facility with a term of five years from the date of the Five-Year Credit Agreement and (ii) a 364-day credit agreement (the “364-Day Credit Agreement” and, together with the Five-Year Credit Agreement, the “Credit Agreements”) with the Agent and the Lenders named therein, which provides for a $2.175 billion senior unsecured revolving credit facility with a term of 364-days from the date of the 364-Day Credit Agreement.”

Apollo Commercial Real Estate Finance, Inc. terminated Indenture with Computershare Trust Company, National Association valued at $500,000,000 (effective 2026-04-24).

“the Trustee delivered a notice of redemption to the holders of the Company’s 4.625% Senior Secured Notes due 2029 (the “Notes”), stating that the Company will redeem in full all $500,000,000 in aggregate principal amount of the outstanding Notes on the redemption date of June 15, 2026”

Apollo Commercial Real Estate Finance, Inc. terminated Amended and Restated Credit Agreement with Bank of America, N.A. valued at $275,000,000 (effective 2026-04-24).

“all commitments under the Revolving Credit Facility were terminated in accordance with the terms of the Revolving Credit Facility. 4.625% Senior Secured Notes due 2029 On the Closing Date, in connection with the closing of the Asset Sale and in accordance with the Indenture, dated as of June 29, 2021”

Apollo Commercial Real Estate Finance, Inc. terminated Term Loan Credit Agreement with Goldman Sachs Bank USA (effective 2026-04-24).

“the Company caused the repayment in full of (i) all outstanding term loans and other obligations under the Term Loan Credit Agreement, dated as of June 13, 2025 (as amended, restated, supplemented or otherwise modified from time to time, the “Term Loan Credit Agreement”), among the Company, as Borrower, the lenders party thereto from time to time, and Goldman Sachs Bank USA, as Administrative Agent and Collateral Agent”

Apollo Commercial Real Estate Finance, Inc. entered into Amended and Restated Management Agreement with ACREFI Management, LLC (effective 2026-04-24).

“Amended and Restated Management Agreement Apollo Commercial Real Estate Finance, Inc., a Maryland corporation (the “Company”), ACREFI Operating, LLC, a subsidiary of the Company (“Operating LLC”), and ACREFI Management, LLC (the “Manager”) have entered into an Amended and Restated Management Agreement (the “A&R Management Agreement”) on April 24, 2026”

Citius Pharmaceuticals, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $5.0 million (effective 2026-04-23).

“On April 23, 2026, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 4,730,457 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 345,686 shares of common stock (the “Pre-funded Warrants”) at an offering price of $0.985 and $0.9849, respectively.”

JOINT Corp entered into Elite Chiro Group Purchase Agreement with Elite Chiro Group valued at $2.3 million (effective 2026-04-20).

“On April 20, 2026, we entered into an Asset Purchase Agreement (the “Elite Chiro Group Purchase Agreement”) with Elite Chiro Group, a California corporation (“Elite Chiro Group”), as buyer, and Gadi Emein, an individual (“Emein”), as guarantor, pursuant to which we will sell to Elite Chiro Group the assets of, and grant franchise rights to, 45 company-owned or managed clinics located in Southern California (the “Elite Chiro Group Transaction”) for an aggregate purchase price of $2.3 million, subject to certain adjustments (the “Purchase Price”).”

Odyssey Health, Inc. entered into Master Technology and Sub-license Agreement with NeuRX Health, Inc. (effective 2025-10-14).

“On April 21, 2026, Odyssey Health, Inc., a Nevada corporation (“ Odyssey ” the “ Company ”) successfully closed the Master Technology and Sub-license Agreement (the “ Agreement ”) with NeuRX Health, Inc. (“ NeuRX ”) which was entered into on October 14, 2025”

Allbirds, Inc. entered into a lease with a subsidiary of QumulusAI, Inc. valued at approximately $2.75 million, three-year.

“the Lessor entered into an approximately $2.75 million, three-year lease agreement with a subsidiary of QumulusAI, Inc. (the “Lessee”) for the Purchased GPU Assets, with an end-of-term purchase option provided to the Lessee.”

Allbirds, Inc. entered into A&R Purchase Agreement with an institutional investor valued at up to $50.0 million (effective 2026-04-19).

“On April 19, 2026, the Purchase Agreement was amended and restated (as so amended and restated, the “ A&R Purchase Agreement ”).”

urban-gro, Inc. entered into Exchange Agreement with Hudson Global Ventures, LLC (effective 2026-04-20).

“Concurrently with the Forbearance Agreement, the Company entered into the Exchange Agreement with Hudson pursuant to which Hudson agreed to reduce a portion of the outstanding loan balance (the “Note Exchange Amount”) and the Company agreed to issue shares of its common stock, par value $0.001 per share (the “Exchange Shares”), to Hudson in exchange therefor.”

urban-gro, Inc. entered into Forbearance Agreement with Hudson Global Ventures, LLC (effective 2026-04-20).

“On April 20, 2026, urban-gro, Inc. (the “Company”) and its wholly owned subsidiary, urban-gro Canada Technologies Inc. (together with the Company, the “Borrower”), entered into a Forbearance Agreement (the “Forbearance Agreement”) and an Exchange Agreement (the “Exchange Agreement”) with Hudson Global Ventures, LLC (“Hudson”).”

Virgin Galactic Holdings, Inc amended Supplemental Indenture with Wilmington Savings Fund Society, FSB (effective 2026-04-24).

“On April 24, 2026, Virgin Galactic Holdings, Inc. (the “Company”) entered into a supplemental indenture (the “Supplemental Indenture”), by and among the Company, the subsidiary guarantors party thereto and Wilmington Savings Fund Society, FSB, as trustee and notes collateral agent for the Company’s existing 9.80% First Lien Notes due 2028 (the "First Lien Notes"), which amends the provisions of the indenture, dated December 18, 2025 (the “Indenture”), by and among the Company, the subsidiary guarantors thereto and Wilmington Savings Fund Society, FSB, as the trustee and the notes collateral agent.”

Senmiao Technology Ltd entered into SPA with certain purchasers valued at $11,000,000 (effective 2026-04-23).

“On April 23, 2026, Senmiao Technology Limited (the “ Company ”) entered into a certain securities purchase agreement (the “ SPA ”) with certain purchasers (the “ Investors ”), pursuant to which the Company agreed to sell an aggregate of up to 10,000,000 units (the “ Units ”), each Unit consisting of one (1) share of its common stock, par value $0.0001 per share (“ Common Stock ”), and four (4) warrants (each, a “ Warrant ”), each to purchase one (1) share of Common Stock (the “ Offering ”), at a purchase price of $1.10 per Unit. The aggregate gross proceeds to the Company from the Offering, if all Units are sold, will be approximately $11,000,000.”

Bio Essence Corp entered into Asset Purchase Agreement with Zhituo Software Co., Limited valued at $3,500,000 (effective 2026-04-20).

“On April 20, 2026, Bio Essence Corp., a California corporation (“Company”) entered into a Asset Purchase Agreement (“APA”) with Zhituo Software Co., Limited, a company incorporated under the laws of Hong Kong (“Zhituo”).”

MeiraGTx Holdings plc entered into Collaboration Agreement with Hologen Neuro AI UK Limited and Hologen Limited and Hologen Neuro AI Limited (effective 2026-04-20).

“the Company, MeiraGTx Neuro UK, MeiraGTx Neuro I, LLC, a Delaware limited liability company (“MeiraGTx Neuro US”), Hologen, HNAI and Hologen Neuro AI UK Limited, a private company limited by shares incorporated in England (“HNAI UK”), entered into the Collaboration and License Agreement (the “Collaboration Agreement”), for the research, development, manufacture and commercialization of the Company’s (i) AAV-GAD investigational gene therapy for the treatment of Parkinson’s disease, AAV-BDNF investigational gene therapy for the treatment of genetic obesity disorders and other potential locally delivered genetic medicines to the central nervous system (the “Clinical Programs”) and (ii) proprietary device designed to effect the local delivery of a gene therapy product into the central nervous system or any topographic or subcutaneous tissue modification on the face and scalp, of humans or animals (the “Delivery Device”), in each case, in accordance with the terms and conditions of the Coll”

MARKETWISE, INC. entered into Settlement Agreement with Mark P. Arnold and JAMA 2021, LLC valued at $12,160,000 (effective 2026-04-21).

“On April 21, 2026, Marketwise, Inc. (the “Company”) and its subsidiary, MarketWise, LLC (together with the Company, “MarketWise”), entered into a Settlement Agreement and Release (the “Settlement Agreement”) with Mark P. Arnold, the Company’s former Chief Executive Officer, and JAMA 2021, LLC (together with Mr. Arnold, the “Arnold Parties”).”

Humacyte, Inc. amended Third Amendment to Distribution Agreement with Fresenius Medical Care Holdings, Inc. valued at low-single-digit royalties on net sales (effective 2026-04-21).

“On April 21, 2026, Humacyte, Inc. (the “Company”) entered into the Third Amendment to Distribution Agreement (the “Amendment”) with Fresenius Medical Care Holdings, Inc. (“Fresenius”), to amend the Distribution Agreement, dated as of June 25, 2018, as amended, between the Company and Fresenius (the “Agreement”).”

Bumble Inc. entered into Super Priority Revolving Credit Agreement with Citibank, N.A, as administrative agent, and the lenders party thereto valued at $50.0 million (effective 2026-04-24).

“On the Closing Date, subsidiaries of the Company entered into the Super Priority Revolving Credit Agreement, by and among the Borrower, Holdings, the Guarantor Subsidiaries party thereto, the lenders party thereto (the “RCF Lenders”), the letter of credit issuers and swing line lenders party thereto, Citibank, N.A, as administrative agent (the “Revolving Administrative Agent”) and the Collateral Agent (the “Revolving Credit Agreement”). Under the Revolving Credit Agreement, the RCF Lenders agreed to provide a revolving credit facility (the “Revolving Credit Facility”) in an aggregate principal committed amount of $50.0 million (including a $10.0 million sublimit for issuance of letters of credit).”

Bumble Inc. entered into Term Loan Credit Agreement with Guggenheim Credit Services, LLC, as administrative agent, and the lenders party thereto valued at $475.0 million (effective 2026-04-24).

“On April 24, 2026 (the “Closing Date”), certain subsidiaries of Bumble Inc. (the “Company”) entered into the Term Loan Credit Agreement (the “Term Loan Credit Agreement”), by and among the lenders party thereto (the “Term Lenders”), Guggenheim Credit Services, LLC, as administrative agent (“Term Loan Administrative Agent”), Alter Domus (US) LLC, as collateral agent (“Collateral Agent”), Buzz BidCo, L.L.C., (“Holdings”), Buzz Finco L.L.C. (“Borrower”) and certain subsidiaries of Borrower, as guarantors (the “Guarantor Subsidiaries”). Under the Term Loan Credit Agreement, the Term Lenders agreed to provide a term loan facility (the “Term Loan Facility”) in an aggregate principal amount of $475.0 million.”

Senti Biosciences, Inc. amended A&R New Enterprise Designation Agreement with New Enterprise Associates 15, L.P. (effective 2026-04-24).

“Senti Biosciences amended and restated that certain Designation Agreement by and between Senti Biosciences and New Enterprise Associates 15, L.P. (“New Enterprise”), dated December 2, 2024 (as amended and restated, the “A&R New Enterprise Designation Agreement”)”

Senti Biosciences, Inc. amended A&R Celadon Designation Agreement with Celadon Partners SPV 24 (effective 2026-04-24).

“Senti Biosciences amended and restated that certain Designation Agreement (the “Celadon Designation Agreement”) by and between Senti Biosciences and Celadon Partners SPV 24 (“Celadon”), dated December 2, 2024 (as amended and restated, the “A&R Celadon Designation Agreement”)”

Senti Biosciences, Inc. entered into Assignment and Assumption Agreement with Senti Biosciences Holdings (effective 2026-04-24).

“per share (“Senti Biosciences Holdings Common Stock”), issued in connection with the Merger are deemed registered under Section 12(b) of the Exchange Act as the common stock of the successor issuer.”

Senti Biosciences, Inc. entered into Agreement and Plan of Merger with Merger Sub (effective 2026-04-24).

“On April 24, 2026, Senti Biosciences completed the Reorganization by implementing the Merger pursuant to the terms of the Merger Agreement.”

Profusa, Inc. entered into Lock-Up Agreement with Ascent Partners Fund LLC (effective 2026-04-20).

“Ascent Partners Fund LLC also entered into a Lock-Up Agreement (the “ Lock-Up Agreement ”) with the Company, dated as of April 20, 2026.”

Profusa, Inc. entered into Side Letter with Ascent Partners Fund LLC (effective 2026-04-20).

“f the Warrant, the Company also entered into a side letter agreement (the “ Side Letter ”) with Ascent. Pursuant to the Side Letter, (i) Ascent waived certain defaults under the Purchase Agreement related to the timing of the delivery of the warrant”

Profusa, Inc. entered into Warrant to Purchase Shares with Ascent Partners Fund LLC (effective 2026-04-20).

“(ii) a Warrant to Purchase Shares of common stock of Profusa, Inc. entitling Ascent to purchase up to 3,333,333 shares of the Company’s common stock, par value $0.0001 per share (the “ Warrant ”), for an aggregate purchase price of $1,000,000.”

Profusa, Inc. entered into Senior Secured Convertible Promissory Note with Ascent Partners Fund LLC valued at $1,111,111.11 (effective 2026-04-20).

“On April 20, 2026, Profusa, Inc., a Delaware corporation (the “ Company ”), completed an additional closing under that certain Securities Purchase Agreement, dated as of February 11, 2025 (as amended, the “ Purchase Agreement ”), by and among the Company, Ascent Partners Fund LLC, a Delaware limited liability company (“ Ascent ”), as initial purchaser, and Ascent, as collateral agent for the purchasers party thereto. In connection with the additional closing, the Company issued to Ascent (i) a Senior Secured Convertible Promissory Note in the aggregate principal amount of $1,111,111.11 (the “ Note ”)”

SURF AIR MOBILITY INC. entered into Note with LamVen valued at up to $15 million (effective 2026-04-20).

“the Company and two of its subsidiaries (such subsidiaries, the "Borrowers") entered into a promissory note with LamVen (the “Note”) in an aggregate principal amount of up to $15 million (the “Maximum Principal Amount”).”

Telomir Pharmaceuticals, Inc. entered into Commitment Agreement with Bayshore Trust (effective 2026-04-22).

“On April 22, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) completed its acquisition of TELI Pharmaceuticals, Inc. (“TELI”) pursuant to the previously announced merger agreement (the “Transaction”).”

NEONC TECHNOLOGIES HOLDINGS, INC. entered into Securities Purchase Agreement with a single institutional investor valued at $10 million (effective 2026-01-29).

“on January 29, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) to issue and sell up to 2,222,222 shares (the “Shares”) of common stock, $0.0001 par value per share of the Company (the “Common Stock”) at a per Share purchase price of $7.20 and five-year warrants to purchase up to 2,222,222 shares of Common Stock at a per share exercise price of $9.00 (the “Warrants” and together with the Shares the “Securities”). The initial closing further to the Agreement consisted of the issuance of 1,388,888 Shares and Warrants to purchase 1,388,888 shares of Common Stock to a single institutional investor at a purchase price of $10 million.”

NEONC TECHNOLOGIES HOLDINGS, INC. entered into second Securities Purchase Agreement with four investors valued at $1,450,004 (effective 2026-02-24).

“on February 24, 2026, the Company entered into a second Securities Purchase Agreement to issue and sell up to the remaining 746,973 Shares at the same per Share purchase price of $7.20 and Warrants to purchase up to 746,973 shares of Common Stock at the same per share exercise price of $9.00.”

NEONC TECHNOLOGIES HOLDINGS, INC. entered into third Securities Purchase Agreement with one investor valued at $1,000,000 (effective 2026-03-20).

“on March 20, 2026, the Company entered into a third Securities Purchase Agreement to issue and sell up to the remaining 545,583 Shares at the same per Share purchase price of $7.20 and Warrants to purchase up to 545,583 shares of Common Stock at the same per share exercise price of $9.00.”

NEONC TECHNOLOGIES HOLDINGS, INC. entered into Securities Purchase Agreement with one investor valued at approximately $2,000,000 (effective 2026-04-20).

“On April 20, 2026, the Company entered into a fourth Securities Purchase Agreement to issue and sell up to the remaining 406,694 Shares at the same per Share purchase price of $7.20 and Warrants to purchase up to 406,694 shares of Common Stock at the same per share exercise price of $9.00.”

Medicus Pharma Ltd. amended Equity Distribution Agreement with Maxim Group LLC and Yorkville Securities, LLC valued at up to $50,000,000 (effective 2026-04-23).

“the Company and the Agents entered into Amendment No. 1 to the Agreement (the "First Amendment", and together with the Agreement, the "Amended Agreement"), pursuant to which the Company increased the size of the aggregate offering amount from $15,349,674 to up to $50,000,000 (the "ATM Upsize")”

Apollo Asset Backed Credit Co LLC amended Fourth Amended and Restated Operating Agreement with Apollo Manager, LLC (effective 2026-04-24).

“On April 24, 2026, Apollo Asset Backed Credit Company LLC (the “Company”) entered into a Fourth Amended and Restated Operating Agreement (the “Fourth A&R Operating Agreement”) with Apollo Manager, LLC (the “Manager”), which amended and restated the Company’s Third Amended and Restated Operating Agreement, dated as of February 28, 2025.”

AEVEX Corp. terminated Credit Agreement with Ankura Trust Company, LLC, PNC Bank, National Association, and the lenders (effective 2026-04-20).

“On April 20, 2026, the Borrower fully repaid and terminated the Credit Agreement, dated as of March 18, 2020, by and among the Borrower, as borrower, Holdings, as holdings, the other loan parties party thereto from time to time, Ankura Trust Company, LLC, as administrative agent, PNC Bank, National Association, as revolving agent and collateral agent and each lender from time to time party thereto, as amended, restated, amended and restated, supplemented or otherwise modified from time to time on or prior to the date hereof.”

AEVEX Corp. entered into New Credit Agreement with Athena Technology Solutions Purchaser, LLC, Bank of America, N.A., and the lenders valued at $375.0 million (effective 2026-04-20).

“On April 20, 2026, in connection with the previously announced closing of AEVEX Corp.’s (the “ Company ”) initial public offering, AEVEX Holdings, LLC (the “ Borrower ”), an operating company of the Company, entered into a new credit agreement (the “ New Credit Agreement ), by and among the Borrower, Athena Technology Solutions Purchaser, LLC (“ Holdings ”), the lenders from time to time party thereto and Bank of America, N.A., as administrative agent, collateral agent, an issuing bank and a swing line lender.”

Elmet Group Co. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at $138,000,000 (effective 2026-04-22).

“On April 22, 2026, The Elmet Group Co., a Delaware corporation, (the “ Company ”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Cantor Fitzgerald & Co. acting as the representative of the several underwriters (the “ Representative ”) of the Company’s firm commitment underwritten initial public offering (the “ Offering ”).”

PEOPLES BANCORP INC entered into Agreement and Plan of Merger with Citizens National Corporation valued at Peoples will acquire Citizens in a cash and stock transaction; each Citizens common share will be co (effective 2026-04-20).

“On April 20, 2026, Peoples Bancorp Inc., an Ohio corporation (“Peoples”), and Citizens National Corporation, a Kentucky corporation (“Citizens”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which Peoples will acquire Citizens in a cash and stock transaction.”

EQUIFAX INC amended Fourth Amendment to Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent valued at $1.5 billion to aggregate principal amount of $2 billion (effective 2026-04-23).

“On April 23, 2026, Equifax Inc. (the “Company”) and certain of its subsidiaries, Equifax Limited, Equifax Canada Co., Equifax International Treasury Services Unlimited Company and Equifax Australia Holdings Pty Ltd (collectively, the “Subsidiary Borrowers”), entered into a Fourth Amendment to Credit Agreement (the “Amendment”)”

ELECTRO SENSORS INC entered into Agreement and Plan of Merger with steute Industrial Controls, Inc. valued at $7.75 per share cash consideration, termination fee of $1,000,000 plus expense reimbursement up to $ (effective 2026-04-20).

“On April 20, 2026, Electro-Sensors, Inc. (“ Electro-Sensors ”, the “ Company ”, “ we ”, “ us ” or “ our ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with steute Industrial Controls, Inc., a Connecticut corporation (“ steute ” or “ Parent ”), and Steute Burwell, Inc., a Minnesota corporation and wholly owned subsidiary of Parent (“ Merger Sub ”).”

UNIVERSAL HEALTH SERVICES INC entered into 2024 Supplemental Indenture with U.S. Bank Trust Company, National Association valued at Supplemental indenture adding certain additional Subsidiary Guarantors as guarantors under the 2024 (effective 2026-04-22).

“a supplemental indenture (the “2024 Supplemental Indenture” and, together with the 2020 Supplemental Indenture and the 2021 Supplemental Indenture, the “Supplemental Indentures”) to that certain Indenture, dated as of September 26, 2024”

UNIVERSAL HEALTH SERVICES INC entered into 2021 Supplemental Indenture with U.S. Bank Trust Company, National Association valued at Supplemental indenture adding certain additional Subsidiary Guarantors as guarantors under the 2021 (effective 2026-04-22).

“Supplemental Indentures On April 22, 2026, the Company, the Subsidiary Guarantors party thereto, and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as trustee, entered into: • a supplemental indenture (the “2020 Supplemental Indenture”) to that certain Indenture, dated as of September 21, 2020 (as amended, supplemented and otherwise modified from time to time prior to the date hereof, the “2020 Indenture”), governing the 2030 Notes; • a supplemental indenture (the “2021 Supplemental Indenture”) to that certain Indenture, dated as of August 24, 2021 (as amended, supplemented and otherwise modified from time to time prior to the date hereof, the “2021 Indenture”), governing the 2026 Notes and the 2032 Notes; and • a supplemental indenture (the “2024 Supplemental Indenture” and, together with the 2020 Supplemental Indenture and the 2021 Suppl”